See more : CRISIL Limited (CRISIL.NS) Income Statement Analysis – Financial Results
Complete financial analysis of CV Sciences, Inc. (CVSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CV Sciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Universal Corporation (UVV) Income Statement Analysis – Financial Results
- Fidelis Insurance Holdings Limited (FIHL) Income Statement Analysis – Financial Results
- HwaCom Systems Inc. (6163.TWO) Income Statement Analysis – Financial Results
- Compañía de Minas Buenaventura S.A.A. (BVN) Income Statement Analysis – Financial Results
- Pono Capital Three, Inc. (PTHR) Income Statement Analysis – Financial Results
CV Sciences, Inc. (CVSI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cvsciences.com
About CV Sciences, Inc.
CV Sciences, Inc. operates as a life science company in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet brand names in various health care sectors, including nutraceutical, beauty care, specialty foods, and pet products. It sells its products through its websites, internet sales, elect distributors, brick and mortar retailers, and select e-tailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. This segment is developing drug candidate CVSI-007 that combines CBD and nicotine in treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.00M | 16.21M | 20.05M | 24.43M | 53.70M | 48.24M | 20.68M | 11.06M | 11.53M | 10.19M | 2.15M | 0.00 | 0.00 |
| Cost of Revenue | 8.92M | 10.66M | 11.43M | 13.42M | 18.61M | 14.37M | 6.19M | 4.06M | 4.42M | 4.39M | 880.47K | 0.00 | 0.00 |
| Gross Profit | 7.09M | 5.55M | 8.62M | 11.01M | 35.09M | 33.88M | 14.49M | 7.00M | 7.11M | 5.80M | 1.27M | 0.00 | 0.00 |
| Gross Profit Ratio | 44.27% | 34.25% | 42.98% | 45.07% | 65.35% | 70.22% | 70.06% | 63.27% | 61.65% | 56.95% | 59.13% | 0.00% | 0.00% |
| Research & Development | 151.00K | 307.00K | 1.19M | 2.94M | 5.88M | 1.89M | 724.33K | 1.16M | 1.32M | 999.28K | 524.48K | 0.00 | 0.00 |
| General & Administrative | 6.55M | 3.89M | 13.93M | 19.36M | 34.39M | 21.75M | 16.25M | 13.13M | 17.75M | 13.36M | 2.37M | 0.00 | 88.09K |
| Selling & Marketing | 2.94M | 8.20M | 11.95M | 11.30M | 12.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.49M | 12.09M | 25.88M | 30.66M | 46.45M | 21.75M | 16.25M | 13.13M | 17.75M | 13.36M | 2.37M | 43.02K | 88.09K |
| Other Expenses | -5.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -12.27K | -8.55K | -73.21K | -34.82K | 0.00 | 43.02K | 0.00 |
| Operating Expenses | 3.73M | 12.40M | 27.06M | 33.60M | 52.33M | 23.63M | 16.98M | 13.91M | 19.07M | 14.36M | 2.89M | 43.02K | 88.09K |
| Cost & Expenses | 12.64M | 23.05M | 38.49M | 47.02M | 70.94M | 38.00M | 23.17M | 17.97M | 23.50M | 18.74M | 3.77M | 43.02K | 88.09K |
| Interest Income | 0.00 | 1.54M | 140.00K | 9.00K | 15.00K | 0.00 | 2.00 | 27.66K | 18.29K | 30.70K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.54M | 140.00K | 9.00K | 0.00 | 153.00K | 506.38K | 1.09M | 968.62K | 615.34K | 372.11K | 2.59K | 2.09K |
| Depreciation & Amortization | 235.00K | 1.06M | 1.50M | 1.47M | 1.53M | 519.00K | 182.00K | 1.05M | 1.01M | 933.60K | 767.25K | 43.02K | 0.00 |
| EBITDA | 3.85M | -5.66M | -14.00M | -21.72M | -15.69M | 10.77M | -4.69M | -12.00M | -10.25M | 236.99K | -1.16M | -2.59K | -88.09K |
| EBITDA Ratio | 24.03% | -36.13% | -86.26% | -88.91% | -30.77% | 22.32% | -11.21% | -52.80% | -95.49% | -75.19% | -39.46% | 0.00% | 0.00% |
| Operating Income | 3.36M | -6.85M | -18.45M | -22.59M | -17.24M | 10.25M | -4.86M | -13.07M | -11.21M | -8.55M | -1.62M | -43.02K | -88.09K |
| Operating Income Ratio | 20.99% | -42.25% | -92.01% | -92.48% | -32.11% | 21.24% | -23.50% | -118.20% | -97.23% | -83.93% | -75.08% | 0.00% | 0.00% |
| Total Other Income/Expenses | -264.00K | -1.41M | 2.81M | -9.00K | 15.00K | -153.00K | -519.00K | -1.07M | -1.02M | 7.24M | -682.86K | -2.59K | -2.09K |
| Income Before Tax | 3.10M | -8.26M | -15.64M | -22.60M | -17.23M | 10.09M | -5.38M | -14.14M | -12.23M | -1.31M | -2.30M | -45.61K | -90.18K |
| Income Before Tax Ratio | 19.35% | -50.98% | -78.02% | -92.52% | -32.08% | 20.92% | -26.01% | -127.85% | -106.10% | -12.87% | -106.78% | 0.00% | 0.00% |
| Income Tax Expense | -6.00K | -47.00K | -87.00K | -317.00K | -615.00K | 93.00K | -481.50K | 1.08M | 895.40K | 541.98K | 372.11K | -43.02K | 0.00 |
| Net Income | 3.10M | -8.21M | -15.55M | -22.28M | -16.61M | 10.00M | -4.90M | -14.14M | -12.23M | -1.31M | -2.30M | -45.61K | -90.18K |
| Net Income Ratio | 19.38% | -50.69% | -77.58% | -91.22% | -30.93% | 20.73% | -23.68% | -127.85% | -106.10% | -12.87% | -106.78% | 0.00% | 0.00% |
| EPS | 0.02 | -0.06 | -0.14 | -0.22 | -0.17 | 0.09 | -0.06 | -0.27 | -0.35 | -0.04 | -0.23 | -0.01 | -0.01 |
| EPS Diluted | 0.02 | -0.06 | -0.14 | -0.22 | -0.17 | 0.09 | -0.06 | -0.27 | -0.35 | -0.04 | -0.23 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 153.95M | 138.03M | 107.82M | 99.91M | 97.86M | 111.12M | 80.43M | 52.66M | 35.14M | 31.58M | 9.88M | 7.00M | 6.97M |
| Weighted Avg Shares Out (Dil) | 153.96M | 138.03M | 107.82M | 99.91M | 97.86M | 114.47M | 80.43M | 52.66M | 35.14M | 31.58M | 9.88M | 7.00M | 6.97M |
CV Sciences, Inc. Enters Into Definitive Agreement to Acquire Extract Labs
CV Sciences, Inc. (CVSI) Q3 2024 Earnings Call Transcript
CV Sciences, Inc. Reports Third Quarter 2024 Financial Results
CV Sciences, Inc. To Announce Third Quarter 2024 Results On November 14, 2024
CV Sciences Launches +PlusHLTH, a New Line of Cannabinoid-Free Supplements
CV Sciences, Inc. (CVSI) Q2 2024 Earnings Call Transcript
CV Sciences, Inc. Reports Second Quarter 2024 Financial Results
CV Sciences, Inc. To Announce Second Quarter 2024 Results On August 13, 2024
CV Sciences, Inc. (CVSI) Q1 2024 Earnings Call Transcript
CV Sciences, Inc. Reports First Quarter 2024 Financial Results
Source: https://incomestatements.info
Category: Stock Reports